14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZLAB vs APLS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs APLS. Trailing 12-month operating profitability (ZLAB -63.0% vs APLS 9.9%) and valuation multiples (ZLAB N/M vs APLS 46.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment63.6% of Rev ($281M)
90D Engineering Disclosures0 Published
APLS Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment54.4% of Rev ($601M)
90D Engineering Disclosures0 Published
Investor FAQ ZLAB vs APLS Key Questions & Quantitative Answers
As of Nov 16, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin). Technically, ZLAB sits in a Neutral phase (RSI 47.1, UNCLASSIFIED options structure) and APLS sits in a Markup phase (RSI 84.5, UNCLASSIFIED options structure).
APLS leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with APLS at +60.9% YoY revenue growth and +0.0% YoY earnings growth on $1.11B TTM revenue (64.3% gross margin, 9.9% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus $1.11B for APLS. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($601M) (0 disclosures) for APLS.
APLS screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas APLS trades at 46.3x Forward P/E, 38.3x Trailing P/E, N/M PEG, and 4.8x EV/Revenue (15.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus APLS (46.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, APLS carries 0.3% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.89x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.54β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.